AtriCure logo updatedAtriCure (NSDQ:ATRC) posted second-quarter results this week that beat the overall consensus on Wall Street.

The Mason, Ohio-based company reported losses of -$16.3 million, or -36¢ per share, on sales of $71.4 million for the three months ended June 30 for a sales growth of 74.84% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were -30¢, 3¢ ahead of The Street, where analysts were looking for sales of $61.1 million.

“Our second-quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of care,” president and CEO Michael Carrel said in a news release. “We are poised for accelerating growth with the recent FDA approval of our EPi-Sense system to improve the lives of millions of patients with long-standing persistent Afib. This approval enriches the foundation of our company, built on core technologies which continue to deliver solid growth as we address vastly underpenetrated markets.”

AtriCure updated its 2021 financial guidance to be in the range of $270 million to $275 million to represent 31% to 33% growth over the year prior.

Shares in ATRC were at a standstill before hours.